前端編輯

管理員身份可於登入後,進行網站的前端管理。

01231520371.jpg

 

主要學歷由最高學歷依次填寫,若仍在學者,請在學位欄填「肄業」

學校名稱 國別 主修學門系所 學位
高雄醫學院 中華民國  醫學系 醫學士
高雄醫學院 中華民國 醫學研究所 碩 士
高雄醫學院 中華民國 醫學研究所 博 士

 

現職及與專長相關之經歷 指與研究相關之專任職務,請依任職之時間先後順序由最近者往前追溯

服務機構 服務部門/系所 職稱 起訖年月(西元年/)

現職:

高雄醫學大學附設醫院

肝膽胰內科 主治醫師 1986/08
高雄醫學大學附設醫院 肝膽胰內科 主任 2000/08
高雄醫學大學 醫學系 教授 2004/08
高雄醫學大學附設醫院 肝炎防治中心主任 主任 2011/08

經歷:

高雄醫學大學附設醫院

內科 總住院醫師 1985/081986/07
高雄醫學大學 醫學系 講師 1987/081993/07
高雄醫學大學 醫學系 副教授 1993/082004/07
高雄醫學大學 超音波室 主任 2000/082003/10
高雄醫學大學附設醫院 臨床教育訓練部 主任 2003/082004/07
高雄醫學大學 研發處校務發展組 組長 2005/082006/08
高雄醫學大學 醫學系 主任 2006/082009/07
高雄醫學大學 產學推動中心 主任 2009/082011/07
高雄醫學大學附設醫院 臨床試驗中心主任 主任 2011/082012/07
高雄醫學大學附設醫院 行政室 副院長 2011/082012/07
高雄醫學大學附設醫院 臨床醫學研究部 主任 2011/082013/07

 

專長

  1. 內科學
  2. 肝膽胰內科
  3. 超音波診斷學
  4. 消化器內視鏡

 

著作目錄

2015

  1. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML, Tung HD. J Gastroenterol Hepatol. 2015 May;30(5):879-84.
  2. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in taiwan. Yu ML, Yeh ML, Tsai PC, Huang CI, Huang JF, Huang CF, Hsieh MH, Liang PC, Lin YH, Hsieh MY, Lin WY, Hou NJ, Lin ZY, Chen SC, Dai CY, Chuang WL, Chang WY. Medicine (Baltimore). 2015 Apr;94(13):e690.
  3. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, Liang PC, Lin YH, Hsieh MY, Yang HL, Huang JF, Lin ZY, Chen SC, Yu ML, Chuang WL. J Hepatol. 2015 Mar;62(3):512-8.
  4. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Gut. 2015 Feb;64(2):303-11.
  5. Clinical utility of a simple primary culture method in hepatocellular carcinoma patients. Lin ZY, Wu CC, Chuang YH, Chuang WL. J Gastroenterol Hepatol. 2015 Feb;30(2):352-7.
  6. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Yeh ML, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML, Chuang WL. Kaohsiung J Med Sci. 2015 Feb;31(2):77-82.
  7. Association between response to pegylated interferon/ribavirin therapy and ribavirin levels. Dai CY, Yu ML, Chuang WL. Hepatology. 2015 Jan;61(1):408-9.
  8. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. Colvin RA, Tanwandee T, Piratvisuth T, Thongsawat S, Hui AJ, Zhang H, Ren H, Chen PJ, Chuang WL, Sobhonslidsuk A, Li R, Qi Y, Praestgaard J, Han Y, Xu J, Stein DS; ABF656A2206 Study Group. J Gastroenterol Hepatol. 2015 Jan;30(1):184-91.
  9. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, Gane E, Lim SG, Fainboim H, Foster GR, Safadi R, Rizzetto M, Manns M, Bao W, Trylesinski A, Naoumov N. J Hepatol. 2015 Jan;62(1):41-7.
  10. Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. Liu TW, Yeh ML, Huang CF, Lin IL, Huang JF, Dai CY, Chen YL, Chuang WL, Yu ML. Kaohsiung J Med Sci. 2015 Jan;31(1):26-33.
  11. Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients. Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL. PLoS One. 2015 Apr 2;10(4):e0122259.

 

2014

  1. Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3. Dai CY, Chuang WL, Yu ML. Hepatology. 2014 Dec;60(6):2129-30.
  2. A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C. Dai CY, Chuang WL, Yu ML. Hepatology. 2014 Dec;60(6):2128-9.
  3. Novel quasi-subgenotype D2 of hepatitis B virus identified in Taiwanese aborigines. Tran H, Yu ML, Dai CY, Lin IL, Yeh ML, Chuang WL, Abe K. Virus Genes. 2014 Aug;49(1):30-7.
  4. Cirrhosis as a risk factor for tuberculosis infection--a nationwide longitudinal study in Taiwan. Lin YT, Wu PH, Lin CY, Lin MY, Chuang HY, Huang JF, Yu ML, Chuang WL. Am J Epidemiol. 2014 Jul 1;180(1):103-10.
  5. Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. Yeh ML, Huang CF, Hsieh MY, Huang JF, Dai CY, Yu ML, Chuang WL. J Clin Virol. 2014 Jul;60(3):206-14.
  6. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, Yang JF, Lin ZY, Chen SC, Wang LY, Dai CY, Huang JF, Chuang WL, Yu ML. J Hepatol. 2014 Jul;61(1):67-74.
  7. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Hsi E, Huang CF, Dai CY, Juo SH, Chou WW, Huang JF, Yeh ML, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML. Antiviral Res. 2014 May;105:135-42.
  8. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection. Huang CI, Huang CF, Huang JF, Dai CY, Yeh ML, Hsieh MY, Lin ZY, Chen SC, Wang LY, Yu ML, Chuang WL. J Gastroenterol Hepatol. 2014 May;29(5):1012-8.
  9. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; FORMOSA-LIKE group. J Hepatol. 2014 Feb;60(2):253-9.
  10. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study. Tseng KC, Chen CY, Tsai HW, Chang TT, Chuang WL, Hsu PI, Liu WC, Cheng PN. Antivir Ther. 2014;19(8):755-64.
  11. Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients. Chang JM, Huang CF, Chen SC, Dai CY, Yeh ML, Huang JF, Kuo HT, Chuang WL, Yu ML, Hwang SJ, Chen HC. Int J Med Sci. 2014 Mar 8;11(5):436-41.
  12. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC, Chuang WL; Taiwan NA-Registry Group. J Gastroenterol Hepatol. 2014 Jan;29(1):185-92.
  13. Abbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapy. Yeh ML, Huang CF, Huang CI, Liu SF, Yang HL, Hsieh MY, Huang JF, Dai CY, Chuang WL, Yu ML. PLoS One. 2014 Jul 7;9(7):e101790.
  14. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF, Chang K, Lin WR, Lin CY, Chen TC, Huang JF, Dai CY, Yu ML, Chuang WL. PLoS One. 2014 Apr 10;9(4):e94791.

 

2013

  1. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Ann Intern Med. 2013 Dec 3;159(11):729-38.
  2. Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy? Dai CY, Chuang WL, Yu ML. Hepatology. 2013 Oct;58(4):1519-20.
  3. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. Dai CY, Tseng TC, Wong GL, Huang JF, Wong VW, Liu CJ, Yu ML, Chuang WL, Kao JH, Chan HL, Chen DS. J Antimicrob Chemother. 2013 Oct;68(10):2332-8.
  4. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Lin ZY, Wu CC, Chuang YH, Chuang WL. Life Sci. 2013 Sep 3;93(8):323-8.
  5. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML. J Gastroenterol Hepatol. 2013 Sep;28(9):1515-20.
  6. Outcome assessment in acute pancreatitis patients. Lee WS, Huang JF, Chuang WL. Kaohsiung J Med Sci. 2013 Sep;29(9):469-77.
  7. Association between gallbladder stones and chronic hepatitis C: ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan. Dai CY, Lin CI, Yeh ML, Hsieh MH, Huang CF, Hou NJ, Hsieh MY, Huang JF, Lin ZY, Chen SC, Wang LY, Chang WY, Chen JS, Yu ML, Chuang WL. Kaohsiung J Med Sci. 2013 Aug;29(8):430-5.
  8. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Wong KM, Yeh ML, Chuang SC, Wang LY, Lin ZY, Chen SC, Tsai JF, Wang SN, Kuo KK, Dai CY, Yu ML, Lee KT, Chuang WL. Indian J Gastroenterol. 2013 Jul;32(4):253-7.
  9. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ; Taiwan Liver-Net Consortium. Hepatology. 2013 Jun;57(6):2135-42.
  10. Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts. Lin ZY, Chuang WL. Kaohsiung J Med Sci. 2013 Jun;29(6):312-8.
  11. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. Huang CF, Yu ML, Kao JH, Tseng TC, Yeh ML, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Liu CH. J Clin Virol. 2013 Apr;56(4):293-8.
  12. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, Kao JH. Hepatology. 2013 Mar;57(3):934-43.
  13. Glucose abnormalities in hepatitis C virus infection. Huang JF, Yu ML, Dai CY, Chuang WL. Kaohsiung J Med Sci. 2013 Feb;29(2):61-8.
  14. Host factors determining the efficacy of hepatitis C treatment. Chuang WL, Yu ML. J Gastroenterol. 2013 Jan;48(1):22-30.
  15. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML. PLoS One. 2013;8(3):e58882.

 

2012

  1. High therapeutic concentration of prazosin up-regulates angiogenic IL6 and CCL2 genes in hepatocellular carcinoma cells. Lin ZY, Chuang WL. Biomed Pharmacother. 2012 Dec;66(8):583-6.
  2. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Lin ZY, Chuang YH, Chuang WL. Biomed Pharmacother. 2012 Oct;66(7):525-9.
  3. Dickkopf-1 and hepatocellular carcinoma. Tsai JF, Jeng JE, Chuang WL. Lancet Oncol. 2012 Oct;13(10):e410; author reply e410-1.
  4. Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Lin ZY, Chuang WL. Biomed Pharmacother. 2012 Sep;66(6):454-8.
  5. Waist circumference, body mass index, serum uric acid, blood sugar, and triglyceride levels are important risk factors for abnormal liver function tests in the Taiwanese population. Hsieh MH, Lin WY, Chien HH, Chien LH, Huang CK, Yang JF, Chang NC, Huang CF, Wang CL, Chuang WL, Yu ML, Dai CY, Ho CK. Kaohsiung J Med Sci. 2012 Sep;28(9):470-6.
  6. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Huang JF, Yu ML, Huang CF, Juo SH, Dai CY, Hsieh MY, Hou NJ, Yeh ML, Hsieh MH, Yang JF, Lin ZY, Chen SC, Shin SJ, Chuang WL. Liver Int. 2012 Jul;32(6):962-9.
  7. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Hsi E, Juo SH, Dai CY, Chuang WL, Yu ML. Antiviral Res. 2012 Feb;93(2):239-44.
  8. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. Hsieh MY, Dai CY, Lee LP, Huang JF, Chuang WL, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML. Kaohsiung J Med Sci. 2012 Feb;28(2):86-93.
  9. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Gut. 2012 Jan;61(1):128-34.
  10. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2012 Jan;56(1):34-40.
  11. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Kao JH. PLoS One. 2012;7(12):e52048.
  12. Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. Lu MY, Huang JF, Liao YC, Bai RK, Trieu RB, Chuang WL, Yu ML, Juo SH, Wong LJ. Transl Res. 2012 Jan;159(1):58-9.
Go to top